Navigation Links
Aspreva Sends Materials for Special Meeting to be Held December 17

Shareholders and Optionholders to Vote on Proposed Plan of Arrangement with


VICTORIA, Nov. 23 /PRNewswire-FirstCall/ - Aspreva Pharmaceuticals Corporation (NASDAQ: ASPV; TSX: ASV) today announced that meeting materials regarding a special meeting to consider the proposed statutory plan of arrangement ("Arrangement") with Galenica Group (SWX: GALN) have been mailed to Aspreva shareholders and optionholders of record. Copies of the meeting materials, including the management information circular and forms of proxy, are available on the United States Securities and Exchange Commission's website at, and on the Canadian provincial securities authorities SEDAR website at

As indicated in the management information circular mailed today, Aspreva's Board of Directors has approved the Arrangement and recommends that Aspreva shareholders vote in favor of the resolutions approving the Arrangement at the special meeting. As previously announced on October 17, 2007, Aspreva entered into a combination agreement with Galenica Group under which Galenica, through a wholly-owned subsidiary, agreed to acquire all of Aspreva's outstanding shares at a price of US$26.00 per share in cash. The total value of the transaction is approximately US$915 million.

On November 15, 2007 Aspreva obtained an interim order from the British Columbia Supreme Court approving, among other things, the holding of a special meeting of Aspreva shareholders and optionholders to consider the Arrangement. The special meeting will be held on December 17, 2007 at 10:00AM (Pacific) at the Four Seasons Hotel, 791 West Georgia Street, Vancouver, British Columbia. The record date for determining shareholders and optionholders entitled to receive notice of and vote at the special meeting has been fixed at the close of business on November 9, 2007.

Subject to approval by the shareholders and optionholders at the special meeting and all regulatory approvals being obtained or concluded, the Court hearing regarding the final order to approve the Arrangement is currently scheduled to take place on December 18, 2007, with closing of the transaction anticipated on January 3, 2008.

Financial and Legal Advisors

Lazard Freres & Co. LLP and Lehman Brothers Inc. have acted as financial advisors to Aspreva with respect to the Arrangement. Aspreva's Canadian legal advisors are Farris, Vaughan, Wills & Murphy LLP and McCarthy Tetrault LLP, while its United States legal advisors are Cooley Godward Kronish LLP.

About Galenica

Galenica is a diversified Group active throughout the healthcare market which, among other things, develops, manufactures and markets pharmaceutical products, runs pharmacies, provides logistical services and access to databases and sets up networks. The Galenica Group enjoys a leading position in all its areas of activity - pharmaceutical manufacturing, pre-wholesaling, distribution, healthcare information and retailing. A large part of the Group's income is generated by international operations. For more information please visit

About Aspreva

Aspreva is a global pharmaceutical company focused on identifying, developing, and, upon approval, commercializing evidence-based medicines for patients living with less common diseases. Aspreva common stock is traded on the NASDAQ Global Select Market under the trading symbol ASPV and on the Toronto Stock Exchange under the trading symbol ASV. Learn more about the company at

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 and forward-looking information within the meaning of applicable securities laws in Canada (collectively, "forward-looking statements"). The words "anticipates", "believes", "budgets", "could", "estimates", "expects", "forecasts", "intends", "may", "might", "plans", "projects", "schedule", "should", "will", "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this news release include, but are not limited to, statements about: the potential acquisition of Aspreva by Galenica in an all cash transaction valued at USD$26.00 per outstanding share (the "Acquisition"); a special meeting of Aspreva's shareholders to consider the Acquisition, currently scheduled for December 2007; and the approval of the Acquisition by Aspreva's shareholders and the Canadian regulatory authorities.

With respect to the forward-looking statements contained in this news release, Aspreva has made numerous assumptions regarding, among other things: Galenica's ability to finance the Acquisition valued at USD$26.00 per outstanding share; the ability of Aspreva and Galenica to satisfy all of the closing conditions to complete the Acquisition; Aspreva's ability to protect its intellectual property rights and to not infringe on the intellectual property rights of others; and Aspreva's ability to comply with applicable governmental regulations and standards. Readers are cautioned that the plans, intentions or expectations disclosed in any forward-looking statements and underlying assumptions may not be achieved and that they should not place undue reliance on any forward-looking statement. Actual results or events could differ materially from the plans, intentions, expectations, and assumptions expressed or implied in any forward-looking statements as a result of numerous risks, uncertainties and other factors, including those relating to: the possibility of not satisfying all of the closing conditions to complete the Acquisition; the possibility that Aspreva's shareholders do not approve the Acquisition at the special meeting of shareholders; risks related to integration of acquisitions; difficulties or delays in obtaining regulatory approvals; competition from other pharmaceutical or biotechnology companies; economic and capital market conditions; and currency exchange rates.

For a more thorough discussion of the risks associated with Aspreva's business, see the "Risk Factors" section in Aspreva's Quarterly Report on Form 10-Q for the quarter ended September 30, 2007, filed with the U.S. Securities and Exchange Commission at and with securities regulatory authorities in Canada at Although we have attempted to identify important risks, uncertainties and other factors that could cause actual results or events to differ materially from those expressed or implied in the forward-looking statements, there may be other factors that cause actual results or events to differ from those expressed or implied in the forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and Aspreva undertakes no obligation to revise or update any forward-looking statements as a result of new information, future events or otherwise after the date hereof.

CONTACT: Sage J. Baker, Vice President, IR & Corporate Communications, Aspreva Pharmaceuticals, (250) 708-4270,

SOURCE Aspreva Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Aspreva to Announce 2007 Third Quarter Results on October 31st
2. Aspreva Announces Preliminary Revenues for Third Quarter 2007
3. Aspreva to be Acquired by Galenica For US$915 Million
4. Arrow International Sends Letter Reminding Shareholders to Vote White Proxy Card in Support of Teleflex Merger and Election of Current Board of Directors
5. Pelosi and Reid: Congress Sends President Bush Bipartisan Childrens Health Insurance Bill
6. FORGET THE JONESES, This is All About Keeping up With the Walkers as the Los Angeles Jewish Home Sends Out an Invite to Everyone Named Walker in the United States
7. Bayer Plants Trees With Chartiers Valley Intermediate School Students, Provides Free Environmental Education Materials
8. Jefferson specialists studying innovative surgery for effectively treating sleep apnea
9. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
10. Physician Skin Care Specialist Says Proposed New Rules for Sunscreen Products Will Better Protect the Public
11. Symmetry Medical Completes Acquisition Of Specialty Surgical Instruments
Post Your Comments:
(Date:12/1/2015)... CA (PRWEB) , ... December 01, 2015 , ... ... States, today announced that its iconic bottle has won top honors in Beverage World ... The Company also announced that it has been selected as a 2015 U.S.A. ...
(Date:12/1/2015)... Houston, TX (PRWEB) , ... December 01, 2015 , ... ... owner of Vitenas Cosmetic Surgery, has been named by MedEsthetics magazine as the Best ... best of the best among the many elite aesthetic physicians honored by the industry ...
(Date:12/1/2015)... ... 01, 2015 , ... Speech and physical therapies are traditionally ... technologies and under the right circumstances, these practices can be merged. This ... to his or her therapeutic sessions, as well as gives the physical and ...
(Date:12/1/2015)... ... December 01, 2015 , ... Growth in medical payments per ... decreases in utilization of hospital and nonhospital care, according to a recent study by ... for Louisiana, 16th Edition , found medical payments per claim with more than seven ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... identification tests to continue the expansion of the company’s growing product line of ... for Chinook (Oncorhynchus tshawytscha) and Sockeye (Oncorhynchus nerka) – allow InstantLabs to offer ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... , Dec. 1, 2015  Athletic apparel ... founder have agreed to pay $1.35 million to ... advertised the company,s copper-infused compression clothing would relieve ... arthritis and other diseases. Tommie ... requires the company and its founder and chairman ...
(Date:12/1/2015)... 2015 Pharma Tech Outlook recently conducted a ... Data Management Solution Providers - 2015 .  After careful ... CEOs, CIOs, VCs, analysts, and the Pharma Tech Outlook ... top 10 clinical data management solution providers (check out ... and 36 respectively). --> ...
(Date:12/1/2015)... and PITTSBURGH , Dec. ... announced that it expects to be the first to ... funded by international donors, TLE400 (Tenofovir Disoproxyl Fumarate 300 ... for $99 per patient, per year. Mylan partnered with ... The significantly reduced price could generate savings of tens ...
Breaking Medicine Technology: